MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clbc.2026.06.012

Медицинская библиотека · Clinical breast cancer · 2026

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.

Filipits Martin, Gruber Viktoria, Singer Christian F, Fitzal Florian, Bago-Horvath Zsuzsanna, Greil Richard, Balic Marija, Regitnig Peter, Toro-Bauer Nancy, Hulla Wolfgang, Egle Daniel, Lizarraga Daneida, Baker Alice, Kaldate Rajesh, Satya Malini, Weidler Jodi, Bates Michael, Campbell Scott, Hlauschek Dominik, Dubsky Peter, Gnant Michael

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The aim of this study was to validate the Xpert Breast Cancer Insight (BC Insight) test. BC Insight is a multigene assay consisting of three target genes and three reference genes.

MATERIALS AND

METHODS

We studied the BC Insight test in 1278 formalin-fixed, paraffin-embedded surgical specimens from postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer with 0-3 involved lymph nodes. Time to distant recurrence (DR) and overall survival (OS) were analyzed using Cox models.

RESULTS

The BC Insight test categorized 764 of 1089 (70.2%) evaluable patients as "low risk". The Xpert BC Insight Risk Score (XRS) was prognostic for DR (hazard ratio (HR) 1.93, 95% confidence interval (CI) 1.58 to 2.35, P<0.0001; C-index 0.73) and OS (HR 1.45, 95% CI 1.26 to 1.67, P<0.0001; C-index 0.65). At 10 years, 95.3% of Xpert BC Insight Risk Category (XRC) low-risk patients were metastasis-free and 89.6% were alive, compared with 85.6% and 77.1% of XRC high-risk patients, respectively (absolute DR risk difference 9.7%, P<0.0001; absolute risk of death difference 12.5%, P<0.0001).

CONCLUSIONS

XRS and XRC are prognostic for DR in postmenopausal women with ER-positive, HER2-negative primary breast cancer. Furthermore, the BC Insight test accurately predicted OS in these patients, particularly in patients with 1-3 involved lymph nodes.

Для цитирования: Filipits Martin, Gruber Viktoria, Singer Christian F, Fitzal Florian, Bago-Horvath Zsuzsanna, Greil Richard, Balic Marija, Regitnig Peter, Toro-Bauer Nancy, Hulla Wolfgang, Egle Daniel, Lizarraga Daneida, Baker Alice, Kaldate Rajesh, Satya Malini, Weidler Jodi, Bates Michael, Campbell Scott, Hlauschek Dominik, Dubsky Peter, Gnant Michael. The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.. Clinical breast cancer. 2026. DOI: 10.1016/j.clbc.2026.06.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.